background: The aim of this meta-analysis was to evaluate the role of androgens or androgen-modulating agents on the probability of pregnancy achievement in poor responders undergoing IVF. methods: Medline, EMBASE, CENTRAL, Scopus and Web of Science databases were searched for the identification of randomized controlled trials evaluating the administration of testosterone, dehydroepiandrosterone (DHEA), aromatase inhibitors, recombinant luteinizing hormone (rLH) and recombinant human chorionic gonadotrophin (rhCG) before or during ovarian stimulation of poor responders.
Introduction
Despite the advancement in assisted reproduction technologies, poor ovarian response is still considered to be one of the most challenging tasks in reproductive medicine (Tarlatzis et al., 2003; Kyrou et al., 2009) . Although a universal definition of poor ovarian response has not been utilized in the relevant studies that are currently available in the literature (Surrey and Schoolcraft, 2000; Kyrou et al., 2009) , poor ovarian response is considered to be an inadequate response to ovarian stimulation, defined usually by a low number of oocytes retrieved or a low number of developing follicles and low estradiol concentration in a previous or in the running, respectively, IVF cycle (Tarlatzis et al., 2003) .
Poor responders represent a significant proportion among women undergoing ovarian stimulation for IVF, ranging from 9 to 24% (BenRafael et al., 1991; Jenkins et al., 1991; Surrey and Schoolcraft, 2000) . Given the severely diminished probability of pregnancy after IVF in these patients, various interventions have been proposed, without, however, the identification of an indisputably efficacious treatment (Kyrou et al., 2009) . Among these interventions, data suggest that growth hormone addition , as well as embryo transfer (ET) performance on Day 2 instead of Day 3, might be beneficial, whereas no benefit has been confirmed regarding other proposed treatments (Kyrou et al., 2009) . Nevertheless, in most of these cases data are quite limited and thus, a potential beneficial effect cannot be excluded (Kyrou et al., 2009; Venetis et al., 2010) .
It has been suggested that the accumulation of androgens in the micro milieu of the primate ovary, plays a critical role in early follicular development and granulosa cell proliferation ). Androgen excess has been shown to stimulate early stages of follicular growth Weil et al., 1998) and increase the number of preantral and antral follicles (Hillier et al., 1997; Weil et al., 1998 Weil et al., , 1999 . In addition, increased intraovarian concentration of androgens seems to augment follicle stimulating hormone (FSH) receptor expression in granulosa cells (Weil et al., , 1999 and thus, potentially lead to enhanced responsiveness of ovaries to FSH (Hillier and De Zwart, 1981; Harlow et al., 1986; Vendola et al., 1998; Weil et al., 1998) . Besides these experimental data, further clinical observations on women with polycystic ovary syndrome or testosteronetreated female transsexuals, suggest that exposure to exogenous androgens may lead to increased number of developing follicles, regardless of gonadotrophin stimulation (Futterweit and Deligdisch, 1986; Spinder et al., 1989; Hugues and Durnerin, 2005) . Furthermore, it has been reported that inadequate levels of endogenous androgens are associated with decreased ovarian sensitivity to FSH and low pregnancy rates after IVF (Frattarelli and Peterson, 2004 ).
On the basis of these data, it has been hypothesized that increasing androgen concentration in the ovarian micro milieu in poorly responding patients might lead to an increase in the number and the maturity of oocytes after ovarian stimulation for IVF. Hence, the use of various androgens and/or androgen-modulating agents has been proposed. These interventions include: (i) pretreatment with transdermal testosterone (Balasch et al., 2006) , (ii) pretreatment with dehydroepiandrosterone (DHEA) (Casson et al., 2000) , (iii) addition of aromatase inhibitors Casper, 2001, 2002) , (iv) addition of recombinant luteinizing hormone (rLH) (Ferraretti et al., 2004) and (v) addition of human chorionic gonadotrophin (hCG) during ovarian stimulation (Ferrari et al., 2002; Berkkanoglu et al., 2007) .
Transdermal testosterone or DHEA pretreatment
Pretreatment with transdermal testosterone or DHEA has been suggested as a safe and effective way of increasing the intraovarian androgen concentration (Casson et al., 2000; Balasch et al., 2006) . Recently published, randomized controlled trials (RCTs) have evaluated transdermal testosterone (Massin et al., 2006; Kim et al., 2011) or DHEA pretreatment (Wiser et al., 2010) in poor responders undergoing ovarian stimulation for IVF, with inconclusive results.
Addition of aromatase inhibitors
Similarly, it has been advocated that the use of aromatase inhibitors could be also beneficial. This is based on the fact that aromatase activity is the key component for the production of estrogens from androgens in granulosa cells. Thus, inhibition of aromatase activity could increase the intraovarian concentration of androgens by blocking their aromatization to estrogens (Mitwally and Casper, 2002) . The RCTs that have recently been conducted, evaluating aromatase inhibitors addition during ovarian stimulation are also inconclusive (Kashyap et al., 2005; Ozmen et al., 2009) .
Pretreatment or addition of rLH during ovarian stimulation with gonadotrophins
According to the 'two cell-two gonadotrophin' theory, follicular steroidogenesis would not take place without the presence of luteinizing hormone (LH), since LH stimulates the production of androgens from theca cells (Hillier et al., 1994) . Thus, luteinizing hormone activity is fundamental in maintaining adequate concentrations of intraovarian androgens and promoting adequate steroidogenesis and follicular growth. At the same time, it has been suggested that using GnRH analogues for pituitary suppression during ovarian stimulation may eventually lead to extremely low levels of endogenous LH and compromise the probability of pregnancy (Westergaard et al., 2000; Humaidan et al., 2002) . Therefore, it has been supported that pretreatment with rLH (Durnerin et al., 2008) or addition of rLH (Humaidan et al., 2004) during ovarian stimulation with recombinant gonadotrophins could optimize ovarian stimulation and thus, might be beneficial for poor responders (Mochtar et al., 2007) . Although many investigators have attempted to evaluate the effectiveness of rLH addition in this category of patients in the context RCTs (Ferraretti et al., 2004; Berkkanoglu et al., 2007; Barrenetxea et al., 2008) , it still remains a considerable controversy.
Addition of hCG
It has already been demonstrated that LH activity provided by hCG addition in the late stages of ovarian stimulation is able to promote and complete the growth of large follicles (Filicori et al., 2002 (Filicori et al., , 2005 . Hence, similarly to rLH, pretreatment with or addition of hCG during ovarian stimulation might be a promising alternative approach for poor responders undergoing IVF.
In view of the conflicting or inconclusive data regarding the efficacy of the proposed interventions, the aim of this systematic review and meta-analysis is to evaluate the administration of androgens and androgen-modulating agents on the probability of pregnancy achievement in poor responders undergoing ovarian stimulation with gonadotrophin releasing hormone (GnRH) analogues and gonadotrophins for IVF.
Methods

Search strategy
A computerized literature search in MEDLINE, EMBASE, CENTRAL, ISI Web of Science and SCOPUS covering the period until April 2011 was performed independently by two reviewers (C.A.V. and J.K.B) aiming to identify RCTs that evaluated the following research question: does administration of testosterone or DHEA or aromatase inhibitors or recombinant LH or hCG increase the probability of pregnancy in poor responders undergoing ovarian stimulation with GnRH analogues and gonadotrophins for IVF? For this purpose, a search strategy with keywords aiming to identify three different terms in each case was used. These terms included 'Intervention', 'Population' and 'Setting'. Various synonyms describing each term were entered as free-text terms in the electronic databases in an attempt to maximize the sensitivity of the search strategy (Table I) . Additionally, the citation lists of all relevant publications and review articles were hand-searched. Meeting proceedings of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine were also hand-searched for the identification of relevant studies. No language limitations were applied.
Selection of studies
Criteria for inclusion/exclusion of studies were established prior to the literature search. Studies had to fulfill the following criteria for eligibility: (i) administration of androgens or androgen modulators in the intervention group; (ii) inclusion of women being subjected to IVF using gonadotrophins and GnRH analogues for ovarian stimulation; (iii) inclusion of women characterized as poor responders and (iv) a parallel comparative design using random allocation of patients in the groups to be compared should have been employed. Studies that included asymmetric interventions (co-interventions), besides the one evaluated in each study (e.g. addition of rLH), were excluded. All parallel RCTs evaluating the relevant interventions were included in the current systematic review and meta-analysis, irrespective of the definition of poor ovarian response, the dose and protocol of intervention proposed, the type of gonadotrophin injected, or the type and protocol of GnRH analogue used. Selection of the studies was performed independently by two of the reviewers (C.A.V. and J.K.B). Any disagreement was resolved by discussion. 
Data extraction
Outcomes
The main outcome measure chosen for the current meta-analysis was achievement of pregnancy per patient randomized, expressed as clinical pregnancy (evidence of intrauterine sac with fetal heart activity at 6 -8 weeks of gestation) or as live birth. Secondary outcome measures included duration of gonadotrophin stimulation, total dose of gonadotrophins required for ovarian stimulation, number of cumulus-oocyte complexes (COCs) retrieved, number of embryos transferred, number of metaphase II (MII) oocytes, number of patients with retrieved oocytes, number of patients having an ET, fertilization rate, estradiol levels on the day of hCG, endometrial thickness on the day of hCG, number of follicles ≥17 mm on the day of hCG, global cancellation rate and cancellation rate due to poor response. In case of missing information, the study authors were contacted in order to retrieve relevant data where available.
Quantitative data synthesis
The dichotomous data results for each of the eligible for meta-analysis studies were expressed as risk difference (RD) with 95% confidence intervals (CIs). These results were combined for meta-analysis using the Mantel/Haenszel model (Mantel and Haenszel, 1959) , when using the fixed effects method, and the DerSimonian and Laird (1986), when using the random effects method. When the outcome of interest was of a continuous nature, the differences were pooled across the studies, which provided information on this outcome, resulting in a weighted mean difference (WMD) with 95% CI. The inverse variance method (Hedges and Olkin, 1985) and the DerSimonian and Laird method (DerSimonian and Laird, 1986) were used when the fixed or random effects method were applied, respectively. All results were combined for meta-analysis with Revman Software (Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). Study-to-study variation was assessed by using the x 2 statistic (the hypothesis tested was that the studies are all drawn from the same population, i.e. from a population with the same effect size). A fixed effects model was used where no statistically significant heterogeneity was present, whereas in the presence of statistically significant heterogeneity, a random effects model was applied. Statistical significance was set at a P-level of 0.05. The presence of publication bias was tested by using the Harbord -Egger's test (Harbord et al., 2006) . Subgroup analyses according to the protocol of the proposed intervention (onset of administration, dose, etc.) were a priori planned to be performed, where necessary.
Results
Systematic review
The literature search yielded 2126 publications in total. The titles of these manuscripts were screened, resulting in 106 studies considered potentially eligible to be included in the review. Of the total of 106 relevant manuscripts identified, 76 studies were excluded after the examination of the abstracts and 30 studies were further evaluated by retrieving the full text. Where necessary, the authors were contacted in an attempt to clarify methodological aspects of the study. Finally, after the exclusion of 17 studies (Supplementary data, Table  S1 ), 13 studies were included in the present systematic review and meta-analysis [the study by Berkkanoglu et al. (2007) contributed two comparisons (rLH versus control and rhCG versus control) in the final data set and for this reason is counted as two studies] (Ferraretti et al., 2004; Demirol et al., 2005; Kashyap et al., 2005; Fernández Ramírez et al., 2006; Massin et al., 2006; Berkkanoglu et al., 2007; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008; Ozmen et al., 2009; Wiser et al., 2010; Kim et al., 2011) . A detailed flow chart of this process is presented in Fig. 1 . Characteristics of the studies included in the systematic review are presented in Tables II-IV. The eligible studies were published between 2004 and 2011 and the number of patients included in the study ranged from 33 to 136 patients (median 84). All studies were randomized controlled parallel studies. In the study by Wiser et al., patients who did not achieve a pregnancy in their first cycle, were subsequently submitted to a second cycle with increased duration of DHEA pretreatment (Wiser et al., 2010) . From this study, only the first cycle was included in the present analysis, so that the assumption of independent observations would not be violated. As stated earlier, the study of Berkkanoglu et al. (2007) was a three-armed RCT comparing the addition of rLH or rhCG with a control group. In this case, the comparison between the rLH and the control group was extracted for the calculation of the pooled effect in rLH addition and the data from the comparison of the rhCG group with the control group were used for the rhCG addition meta-analysis.
Randomization method and allocation concealment were reported in 7 (Ferraretti et al., 2004; Kashyap et al., 2005; Massin et al., 2006; Ruvolo et al., 2007; Barrenetxea et al., 2008; Wiser et al., 2010; Kim et al., 2011) and 5 (Fernández Ramírez et al., 2006; Barrenetxea et al., 2008; Ozmen et al., 2009; Wiser et al., 2010; Kim et al., 2011) out of the 12 individual studies, respectively. Definition of poor ovarian response, as well as the primary outcome varied among studies (Table II) . Power analysis was performed in 4 (Kashyap et al., 2005; Massin et al., 2006; Ruvolo et al., 2007; Barrenetxea et al., 2008) studies and financial support was also declared in 4 (Fernández Ramírez et al., 2006; Massin et al., 2006; Ruvolo et al., 2007; Wiser et al., 2010) out of the 12 individual studies (Table II) . To inhibit premature LH surge, GnRH agonists were used in six studies (Ferraretti et al., 2004; Berkkanoglu et al., 2007; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008; Wiser et al., 2010) , whereas in five studies a GnRH antagonist protocol was applied (Demirol et al., 2005; Kashyap et al., 2005; Fernández Ramírez et al., 2006; Ozmen et al., 2009; Kim et al., 2011) . In the study by Massin et al. (2006) both GnRH agonists, as well as GnRH antagonists were used (Table III) , although the proportions of the different GnRH analogue protocols were not statistically different between the two groups compared.
Apart from the evaluated intervention in each study (i.e. transdermal testosterone, DHEA, aromatase inhibitors, rLH or rhCG), ovarian stimulation was performed with the use of recombinant FSH in most of the studies, except for the one study that tested the addition of DHEA in which a combination of recombinant FSH and recombinant LH was used for ovarian stimulation (Wiser et al., 2010) . Gonadotrophin adjustments were reported in eight studies (Ferraretti et al., 2004; Demirol et al., 2005; Fernández Ramírez et al., 2006; Massin et al., 2006; Ruvolo et al., 2007; Barrenetxea et al., 2008; Ozmen et al., 2009; Kim et al., 2011) . HCG was used to trigger final oocyte maturation in all studies, except for three in which this information was not reported (Kashyap et al., 2005; Polidoropoulos et al., 2007; Ozmen et al., 2009) , while the criteria for hCG administration varied across studies (Table III) . Oocyte retrieval was performed 35 -36 h after hCG administration in 10 studies (Ferraretti et al., 2004; Demirol et al., 2005; Fernández Ramírez et al., 2006; Massin et al., 2006; Berkkanoglu et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008; Ozmen et al., 2009; Wiser et al., 2010; Kim et al., 2011) , whereas in the two remaining studies (Kashyap et al., 2005; Polidoropoulos et al., 2007) , the timing of oocyte retrieval was not reported. Fertilization methods included IVF (n ¼ 2) (Ferraretti et al., 2004; Wiser et al., 2010) , ICSI (n ¼ 6) (Demirol et al., 2005; Berkkanoglu et al., 2007; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008; Ozmen et al., 2009) , IVF/ICSI (n ¼ 3) (Fernández Ramírez et al., 2006; Massin et al., 2006; Kim et al., 2011) , whereas in one study the information was not available (Kashyap et al., 2005) . ETs were performed on Day 2 or 3 after oocyte retrieval, while luteal support varied among studies (Table III) . Three studies did not provide details about the type of luteal support used, as only the abstract was available and, although pursued, no contact was established with the authors (Demirol et al., 2005; Kashyap et al., 2005; Polidoropoulos et al., 2007) .
Interventions Pretreatment with transdermal testosterone
Regarding the type of intervention performed, pretreatment with transdermal testosterone gel was applied in two studies (Massin et al., 2006; Kim et al., 2011) , in a dose of 10 and 12.5 mg/day, respectively, starting from 15 to 21 days in the period preceding ovarian stimulation (Table IV) .
Pretreatment with DHEA
DHEA was administered in one study, in a dose of 75 mg/day, 6 weeks before ovarian stimulation (Wiser et al., 2010; Table IV ). 
Addition of aromatase inhibitors
In two studies, the aromatase inhibitor, letrozole, was proposed (Kashyap et al., 2005; Ozmen et al., 2009) . One study was an abstract, reporting only minimal information regarding the intervention protocol (Kashyap et al., 2005) . Communication with the authors to retrieve missing data was attempted, yet no reply was received. In the remaining RCT (Ozmen et al., 2009) , 2.5 mg of letrozole was administered twice a day (2 × 2.5 mg) from Day 3 of ovarian stimulation for five consecutive days (Table IV) .
Addition of recombinant LH
Addition of recombinant LH was evaluated in seven studies, in which the dose was 75 IU/day (n ¼ 2) (Berkkanoglu et al., 2007; Polidoropoulos et al., 2007) , 75-150 IU/day (n ¼ 3) (Ferraretti et al., 2004; Ruvolo et al., 2007; Barrenetxea et al., 2008) and 150 IU/day (n ¼ 2) (Demirol et al., 2005; Fernández Ramírez et al., 2006) . The timing of initiation of rLH addition varied among studies, whereas in all eligible studies rLH was administered until the hCG criteria were met (Table IV) .
Addition of recombinant hCG
One study (Berkkanoglu et al., 2007) evaluated the addition of 75 IU/ day of recombinant hCG to rFSH from the 7th day until completion of ovarian stimulation (Table IV) .
Meta-analysis
Transdermal testosterone pretreatment
Clinical pregnancy rate and live birth rate
Clinical pregnancy rate was significantly increased by 15% in patients that were pretreated with transdermal testosterone when compared with those who were not (RD: +15%, 95% CI: +3 to +26%; fixed effects model; heterogeneity: P ¼ 0.60; Fig. 2a) . Similarly, live birth rate was also increased by 11% in patients who were pretreated with transdermal testosterone (RD: +11%, 95% CI: +0.3 to +22%; fixed effects model; heterogeneity: P ¼ 0.20; Fig. 2b ). Two small studies (Massin et al., 2006; Kim et al., 2011) , evaluating the use of transdermal testosterone pretreatment in 163 patients in total, offered data for these outcomes. The Harbord-Egger's test for the assessment of publication bias could not be performed due to the limited number of studies (n ¼ 2).
Total dose of gonadotrophins required for ovarian stimulation
The total dose of gonadotrophins required for ovarian stimulation was significantly decreased in patients who were pretreated with transdermal testosterone when compared with those who were not (WMD: 2446.2 IUs, 95% CI: 2600.9 to 2291.5; fixed effects model; heterogeneity: P ¼ 0.91). 
Duration of ovarian stimulation
COCs retrieved
The number of COCs retrieved was significantly increased in the patients who were pretreated with transdermal testosterone when compared with the patients who were not (WMD: +1.5 COCs, 95% CI: +0.9 to +2.1; fixed effects model; heterogeneity: P ¼ 0.22). Data on remaining secondary outcomes regarding transdermal testosterone pretreatment are presented in Table V .
DHEA administration before ovarian stimulation
One small study (Wiser et al., 2010) , evaluating the addition of DHEA in 33 patients in total, offered data for the following outcomes.
Clinical pregnancy rate and live birth rate
Clinical pregnancy rates (RD: +11%, 95% CI: 215 to +37%; fixed effects model; heterogeneity: not applicable), and live birth rates (RD: +11%, 95% CI: 210 to +33%; fixed effects model; heterogeneity: not applicable) were not significantly different between patients treated with DHEA before ovarian stimulation and the control group. The Harbord -Egger's test for the assessment of publication bias could not be performed because only one study was available.
COCs retrieved
The number of COCs retrieved was not significantly different in the patients who received DHEA when compared with the patients All of the patients received estrogen-progesterone pretreatment using E2 valerate 1 mg/day and norethridone 5 mg/day for 21 days in the cycle preceding COS.
who did not (WMD: 21.0, 95% CI: 22.23 to +0.23; fixed effects model; heterogeneity: not applicable). Data on remaining secondary outcomes regarding DHEA pretreatment in poor responders undergoing IVF are presented in Table V .
Aromatase inhibitors
Clinical pregnancy rate and live birth rate Clinical pregnancy rates were not significantly different between patients who received aromatase inhibitor and those who did not (RD: +8%, 95% CI: 24.0 to +19.0%; fixed effects model; heterogeneity: P ¼ 0.84; Fig. 3 ). Two studies (Kashyap et al., 2005; Ozmen et al., 2009 ) offered data for this outcome. Data on live birth rates were not available in any of the eligible studies. The Harbord -Egger's test for the assessment of publication bias could not be performed due to the limited number of studies (n ¼ 2).
Total dose of gonadotrophins required for ovarian stimulation
The addition of aromatase inhibitors during ovarian stimulation of poor responders undergoing IVF was associated with a significant decrease in gonadotrophin consumption (WMD: 2870 IUs, 95% CI: 21110.19 to 2629.81; fixed effects model; heterogeneity: not applicable). Only one study (n ¼ 70) offered data for this outcome (Ozmen et al., 2009) .
COCs retrieved
The number of COCs retrieved was not significantly different between patients who received aromatase inhibitors during ovarian stimulation and those who did not (WMD: +0.10 COCs, 95% CI: 20.60 to +0.80; fixed effects model; heterogeneity: not applicable). Only one study (Ozmen et al., 2009 ) offered data for this outcome.
Data on remaining secondary outcomes regarding the addition of aromatase inhibitors are presented in Table V .
Recombinant LH addition
Clinical pregnancy rate and live birth rate A non-significant increase of 6% in clinical pregnancy rates was detected in patients who received rLH when compared with those who did not (95% CI: 20.3 to +13%; fixed effects model; heterogeneity: P ¼ 0.59; Fig. 4 ). Seven studies (Ferraretti et al., 2004; Demirol et al., 2005; Fernández Ramírez et al., 2006; Berkkanoglu et al., 2007; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008) , evaluating the addition of recombinant LH in 603 patients in total, offered data for this outcome. Publication bias was not detected (Harbord-Egger's test: P ¼ 0.69).
Moreover, a subgroup analysis according to dose of rLH administered was performed and no significant difference in the pooled clinical pregnancy RDs was detected between the three subgroups (P ¼ 0.39). When the two studies (Berkkanoglu et al., 2007; Polidoropoulos et al., 2007) in which a dose of 75 IU of rLH was used were combined, clinical pregnancy rates were similar (RD: +2%, 95% CI: 29 to +13%; fixed effects model; heterogeneity: P ¼ 0.85) between the rLH and the control groups. In the three studies that used a variable dose of the dose of 75 -150 IU (Ferraretti et al., 2004; Ruvolo et al., 2007; Barrenetxea et al., 2008) a slightly significant increase of +12% (95% CI: +1 to +24%; fixed effects model; heterogeneity: P ¼ 0.37) in favor of rLH addition was detected, while in the other two studies, where a dose of 150 IU of rLH was used (Demirol et al., 2005; Fernández Ramírez et al., 2006) , clinical pregnancy rate was not significantly different between patients who received rLH and those who did not (RD: +3%, 95% CI: 29 to +15%; fixed effects model; heterogeneity: P ¼ 0.49).
Regarding clinical pregnancy per timing of onset, no significant difference was present with rLH addition either during mid-to-late follicular phase in six studies (Ferraretti et al., 2004; Fernández Ramírez et al., 2006; Berkkanoglu et al., 2007; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008) (RD: +7%, 95% CI: 21 to 
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+14%; fixed effects model; heterogeneity: P ¼ 0.50) or during early follicular phase in one study (Demirol et al., 2005) (RD: +6%, 95% CI: 29 to +20%; fixed effects model; heterogeneity: not applicable). Testing for differences between these two subgroups was also not significant (P ¼ 0.97). Data on live birth rate were available only in one (Ferraretti et al., 2004) out of seven eligible studies. In that study, live birth rate was significantly increased in poor responders who received rLH when compared with poor responders who did not (RD: +19%, 95% CI: +1 to +36%; fixed effects model; heterogeneity: not applicable).
Total dose of FSH required for ovarian stimulation
No significant difference in the total dose of FSH required for ovarian stimulation was present between patients stimulated with rFSH and rLH when compared with patients who were stimulated with rFSH alone (WMD: 2272.85 IUs, 95% CI: 2600.52 to +54.83; random effects model; heterogeneity: P ¼ 0.0004). Six studies (Ferraretti et al., 2004; Fernández Ramírez et al., 2006; Berkkanoglu et 
Duration of ovarian stimulation
Duration of stimulation was not significantly different between patients treated with rLH and those who were not (WMD: 20.31 days, 95% CI: 20.66 to +0.04; random effects model; heterogeneity: P ¼ 0.02). Six studies (Ferraretti et al., 2004; Fernández Ramírez et al., 2006; Berkkanoglu et al., 2007; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008) offered data for this outcome.
COCs retrieved
The number of COCs retrieved was not significantly different between patients who did or did not received rLH (WMD: 20.04, 95% CI: 20.61 to + 0.54; random effects model; heterogeneity: P ¼ 0.002). Five eligible studies (Ferraretti et al., 2004; Fernández Ramírez et al., 2006; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008) Figure 3 Risk difference for clinical pregnancy in patients treated with aromatase inhibitors or not.
Androgens or androgen-modulating agents for poor responders Data on remaining secondary outcomes regarding the addition of rLH in poor responders are presented in Table V .
Recombinant hCG addition
One study (Berkkanoglu et al., 2007) , evaluating the addition of recombinant hCG in 99 patients in total, offered data for the following outcomes.
Clinical pregnancy rate and live birth rate
Clinical pregnancy rate was not significantly different between patients who received rhCG besides rFSH when compared with those stimulated with rFSH alone (RD: 25%, 95% CI: 220 to +10%; fixed effects model; heterogeneity: not applicable). The Harbord-Egger's test for the assessment of publication bias could not be performed because only one study was available. Data on live birth rate were not provided by the only eligible study.
Total dose of gonadotrophins required for ovarian stimulation
The addition of rhCG was associated with a significant decrease in the total dose of FSH required for ovarian stimulation when compared with the control group (WMD: 2552.10 IUs, 95% CI: 21035.16 to 269.04; fixed effects model; heterogeneity: not applicable).
Duration of ovarian stimulation
Duration of stimulation was significantly decreased in patients treated with rhCG when compared with those who were not (WMD: 21.00 days, 95% CI: 21.71 to 20.29; fixed effects model; heterogeneity: not applicable).
Data on remaining secondary outcomes regarding the value of hCG addition in poor responders are presented in Table V .
Discussion
The present systematic review and meta-analysis summarizes the best available evidence regarding the use of androgens or androgenmodulating agents before or during ovarian stimulation with gonadotrophin in poor responders undergoing IVF. Based on the RCTs included in the present meta-analysis, there is limited evidence suggesting that transdermal testosterone pretreatment improves clinical pregnancy and live birth rates. On the other hand, no beneficial effect on pregnancy rates after IVF was detected in poor responders treated with DHEA, aromatase inhibitors or hCG before or during ovarian stimulation.
In the case of rLH addition, data originating only from one study (Ferraretti et al., 2004) support that adding rLH might be beneficial in terms of live birth. Regarding clinical pregnancy rates, however, pooling the data from seven eligible studies did not detect any significant benefit in patients who received rLH when compared with those who did not (Ferraretti et al., 2004; Demirol et al., 2005; Fernández Ramírez et al., 2006; Berkkanoglu et al., 2007; Polidoropoulos et al., 2007; Ruvolo et al., 2007; Barrenetxea et al., 2008) . Although statistical significance was not reached, the magnitude of the effect size and the width of the 95% CI in terms of clinical pregnancy rate (RD: +6%, 95% CI: 20.3 to +13%) might indicate a potentially clinically significant finding (Brahman, 1991) . However, until the addition of further studies confirms or rejects such a theory, the beneficial role of rLH administration in poor responders undergoing ovarian stimulation for IVF cannot be adequately supported by the available data.
Subgroup analyses were only feasible in the case of rLH addition, due to the limited number of studies in the other sets. When the studies were analyzed according to the exact time of initiation of rLH addition no significant differences were detected both within and between the two subgroups of studies. Similarly, when the studies were analyzed according to the doses of rLH used in these studies, no statistically significant difference was present between the three subgroups (75, 75-150 and 150 IU). Nevertheless, it should be noted that in the 75-150 IU subgroup, the pooled effect estimate from the three studies was statistically significant (P ¼ 0.03). Although it cannot be excluded that this finding might reflect an actual underlying effect (i.e. through an optimal dose of rLH), the possibility that it represents a type I error (i.e. a false-positive finding) should also be strongly considered, especially given the multiple statistical comparisons performed (O'Brien and Shampo, 1988) .
This systematic review and meta-analysis of RCTs follows a holistic approach on the role of androgens and androgen-modulating agents in poor responders undergoing IVF. Increasing the production of endogenous intraovarian androgens (through the addition of LH activity in the forms of rLH or hCG), decreasing the conversion of androgens to estrogens (through the addition of aromatase inhibitors), administering exogenous androgens (such as transdermal testosterone or DHEA), are all interventions that aim to increase intra-ovarian Figure 4 Risk difference for clinical pregnancy in patients treated with rFSH + rLH or rFSH alone.
